GLI1 activation is a key mechanism of erlotinib resistance in human non‑small cell lung cancer
Affiliations: Department of Pathology, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94115, USA, Department of Medical Oncology, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China, Zhejiang Provincial Key Laboratory of Applied Enzymology and Precision Medicine Center, Jiaxing, Zhejiang 314006, P.R. China
- Published online on: July 31, 2020 https://doi.org/10.3892/ol.2020.11937
- Article Number: 76
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.